keyword
MENU ▼
Read by QxMD icon Read
search

immune checkpoint

keyword
https://www.readbyqxmd.com/read/29031195/ginsenoside-rg3-attenuates-cisplatin-resistance-in-lung-cancer-by-downregulating-pd-l1-and-resuming-immune
#1
Zhansheng Jiang, Yanfang Yang, Yinli Yang, Yu Zhang, Zhensong Yue, Zhanyu Pan, Xiubao Ren
Programmed death ligand 1 (PD-L1) as one the most important immune checkpoint was verified to involve in chemotherapy resistance in non-small cell lung cancer (NSCLC). Ginsenoside Rg3 is isolated from Chinese herb-Panax ginseng which is recognized to boost immune and has anti-cancer activity against a majority of carcinomas including NSCLC. In this study, we aim to identify whether Rg3 could attenuate the PD-L1 expression induced by resistance to cisplatin and draw out the underlying mechanisms of PD-L1 in this process...
October 11, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29029232/immune-checkpoint-inhibitor-induced-myo-fasciitis
#2
Dimitrios Daoussis, Pantelis Kraniotis, Stamatis-Nick Liossis, Aikaterini Solomou
No abstract text is available yet for this article.
September 27, 2017: Rheumatology
https://www.readbyqxmd.com/read/29028787/relationship-between-pd-l1-expression-and-cd8-t-cell-immune-responses-in-hepatocellular-carcinoma
#3
Chun-Yu Huang, Ying Wang, Guang-Yu Luo, Feng Han, Yong-Qiang Li, Zhong-Guo Zhou, Guo-Liang Xu
As PD-1/PD-L1 immune checkpoint inhibitors exhibited promising clinical outcomes in various types of solid tumors, PD-1/PD-L1 blockades have been explored for the treatment of hepatocellular carcinoma (HCC). However, the association of PD-L1 with antitumor immunoregulation is not clearly defined in HCC. Here, we evaluated the characteristics of PD-L1 expression, CD8 T-cell infiltration and their relationship in HCC. A total of 411 resected tumor specimens from HCC patients were immunostained for PD-L1 and CD8...
November 2017: Journal of Immunotherapy
https://www.readbyqxmd.com/read/29028305/fast-image-guided-stratification-using-anti-programmed-death-ligand-1-gold-nanoparticles-for-cancer-immunotherapy
#4
Rinat Meir, Katerina Shamalov, Tamar Sadan, Menachem Motiei, Gur Yaari, Cyrille J Cohen, Rachela Popovtzer
Cancer immunotherapy has made enormous progress in offering safer and more effective treatments for the disease. Specifically, programmed death-ligand 1 antibody (αPDL1), designed to perform immune checkpoint blockade (ICB), is now considered a pillar in cancer immunotherapy. However, due to the complexity and heterogeneity of tumors, as well as the diversity in patient response, ICB therapy has only a 30 percent success rate, at most; moreover, the efficacy of ICB can be evaluated only two months after start of treatment...
October 13, 2017: ACS Nano
https://www.readbyqxmd.com/read/29027915/a-combination-of-immune-checkpoint-inhibition-with-metronomic-chemotherapy-as-a-way-of-targeting-therapy-resistant-cancer-cells
#5
REVIEW
Irina Kareva
Therapeutic resistance remains a major obstacle in treating many cancers, particularly in advanced stages. It is likely that cytotoxic lymphocytes (CTLs) have the potential to eliminate therapy-resistant cancer cells. However, their effectiveness may be limited either by the immunosuppressive tumor microenvironment, or by immune cell death induced by cytotoxic treatments. High-frequency low-dose (also known as metronomic) chemotherapy can help improve the activity of CTLs by providing sufficient stimulation for cytotoxic immune cells without excessive depletion...
October 13, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29027224/immunomodulation-by-ionizing-radiation-impact-for-design-of-radio-immunotherapies-and-for-treatment-of-inflammatory-diseases
#6
REVIEW
Benjamin Frey, Michael Rückert, Lisa Deloch, Paul F Rühle, Anja Derer, Rainer Fietkau, Udo S Gaipl
Ionizing radiation is often regarded as an element of danger. But, danger responses on the cellular and molecular level are often beneficial with regard to the induction of anti-tumor immunity and for amelioration of inflammation. We outline how in dependence of radiation dose and fraction, radiation itself-and especially in combination with immune modulators-impacts on the innate and adaptive immune system. Focus is set on radiation-induced changes of the tumor cell phenotype and the cellular microenvironment including immunogenic cancer cell death...
November 2017: Immunological Reviews
https://www.readbyqxmd.com/read/29027221/abscopal-immunological-effects-of-radiotherapy-narrowing-the-gap-between-clinical-and-preclinical-experiences
#7
REVIEW
Nikko Brix, Anna Tiefenthaller, Heike Anders, Claus Belka, Kirsten Lauber
Radiotherapy-despite being a local therapy that meanwhile is characterized by an impressively high degree of spatial accuracy-can stimulate systemic phenomena which occasionally lead to regression and rejection of non-irradiated, distant tumor lesions. These abscopal effects of local irradiation have been observed in sporadic clinical case reports since the beginning of the 20th century, and extensive preclinical work has contributed to identify systemic anti-tumor immune responses as the underlying driving forces...
November 2017: Immunological Reviews
https://www.readbyqxmd.com/read/29027218/cell-death-and-immunity-in-cancer-from-danger-signals-to-mimicry-of-pathogen-defense-responses
#8
REVIEW
Abhishek D Garg, Patrizia Agostinis
The immunogenicity of cancer cells is an emerging determinant of anti-cancer immunotherapy. Beyond developing immunostimulatory regimens like dendritic cell-based vaccines, immune-checkpoint blockers, and adoptive T-cell transfer, investigators are beginning to focus on the immunobiology of dying cancer cells and its relevance for the success of anticancer immunotherapies. It is currently accepted that cancer cells may die in response to anti-cancer therapies through regulated cell death programs, which may either repress or increase their immunogenic potential...
November 2017: Immunological Reviews
https://www.readbyqxmd.com/read/29027155/the-role-of-t-cell-immunoglobulin-mucin-3-and-its-ligand-galectin-9-in-antitumor-immunity-and-cancer-immunotherapy
#9
REVIEW
Riyao Yang, Mien-Chie Hung
Cancer treatment in the past few years has been transformed by a new kind of therapy that targets the immune system instead of the cancer itself to reinvigorate antitumor immunity with astonishing results. However, primary and acquired resistance to this type of treatment, namely immune checkpoint blockade (ICB), continue to counter treatment efficacy. In many cases, resistance has been attributed to defective or chronically enhanced interferon signaling and/or upregulation of alternative immune checkpoints, including T-cell immunoglobulin mucin-3 (Tim-3) and its ligand galactin-9 (Gal-9)...
October 11, 2017: Science China. Life Sciences
https://www.readbyqxmd.com/read/29026920/immunotherapy-as-an-option-for-cancer-treatment
#10
REVIEW
Tillmann Rusch, Jagadeesh Bayry, Jens Werner, Ivan Shevchenko, Alexandr V Bazhin
The progress in melanoma immunotherapy highlights the importance of immunotherapy for cancer treatment. Although the concept of immunotherapy emerged in the beginning of the twentieth century, the end of the century signaled the start of modern immunotherapy, which has recently allowed a staggering progress in the field of cancer immunotherapy. Currently, there is a wide variety of immunotherapeutic approaches and critical improvements are continually being made. Among different immunotherapeutic strategies, therapies based on the blockade of immune checkpoint molecules have shown unparalleled efficacy in late-stage cancer patients...
October 12, 2017: Archivum Immunologiae et Therapiae Experimentalis
https://www.readbyqxmd.com/read/29026335/challenging-the-standard-of-care-in-advanced-melanoma-focus-on-pembrolizumab
#11
REVIEW
Raghad M Abdul-Karim, C Lance Cowey
The last several years have seen a dramatic rise in the number of effective therapies that have been shown to improve survival outcomes for patients with advanced melanoma. Among these treatments are the immune checkpoint inhibitors, a new class of immunotherapy, that have demonstrated the ability to improve both response rates and survival outcomes. Pembrolizumab, an immune checkpoint inhibitor that blocks the negative regulatory PD-1 receptor on T-cell lymphocytes, has shown improved efficacy compared to standard therapies with an acceptable tolerability profile...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/29026068/hollow-mno2-as-a-tumor-microenvironment-responsive-biodegradable-nano-platform-for-combination-therapy-favoring-antitumor-immune-responses
#12
Guangbao Yang, Ligeng Xu, Yu Chao, Jun Xu, Xiaoqi Sun, Yifan Wu, Rui Peng, Zhuang Liu
Herein, an intelligent biodegradable hollow manganese dioxide (H-MnO2) nano-platform is developed for not only tumor microenvironment (TME)-specific imaging and on-demand drug release, but also modulation of hypoxic TME to enhance cancer therapy, resulting in comprehensive effects favoring anti-tumor immune responses. With hollow structures, H-MnO2 nanoshells post modification with polyethylene glycol (PEG) could be co-loaded with a photodynamic agent chlorine e6 (Ce6), and a chemotherapy drug doxorubicin (DOX)...
October 12, 2017: Nature Communications
https://www.readbyqxmd.com/read/29025984/synthesis-and-biological-evaluation-of-a-novel-18-f-labeled-adnectin-as-a-pet-radioligand-for-imaging-pd-l1-expression
#13
David J Donnelly, Ralph Adam Smith, Paul Morin, Dasa Lipovsek, Jochem Gokemeijer, Daniel Cohen, Virginie Lafont, Tritin Tran, Erin Lee Cole, Martin Wright, Joonyoung Kim, Adrienne Pena, Daniel Kukral, Douglas D Dischino, Patrick Chow, Jinping Gan, Olufemi Adelakun, Xi-Tao Wang, Kai Cao, David Lueng, Samuel Bonacorsi, Wendy Hayes
The programmed death protein (PD-1) and its ligand (PD-L1) play critical roles in a checkpoint pathway cancer cells exploit to evade the immune system. A same-day PET imaging agent for measuring PD-L1 status in primary and metastatic lesions could be important for optimizing drug therapy. Herein, we have evaluated the tumor targeting of an anti-PD-L1 Adnectin after (18)F-fluorine labeling. Methods: An anti-PD-L1 Adnectin was labeled with (18)F in two steps. This synthesis featured fluorination of a novel prosthetic group, followed by a copper-free click conjugation to a modified Adnectin to generate (18)F-BMS-986192...
October 12, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29025857/endocrine-side-effects-of-cancer-immunotherapy
#14
Priscilla Cukier, Fernando C Santini, Mariana Scaranti, Ana O Hoff
Immune checkpoint inhibitors have recently become a cornerstone for the treatment of different advanced cancers. These drugs, represented mainly by monoclonal antibodies anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4), anti-programmed cell death protein-1 (PD-1) and anti-PD-1 ligand molecules (PD-L1 and L2), have the ability to reactivate the immune system against tumor cells, but can also trigger a myriad of autoimmune side effects, termed immune-related adverse events (irAEs). In particular, there are a number of endocrine related irAEs...
October 12, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29025772/impaired-hla-class-i-antigen-processing-and-presentation-as-a-mechanism-of-acquired-resistance-to-immune-checkpoint-inhibitors-in-lung-cancer
#15
Scott Gettinger, Jungmin Choi, Katherine Hastings, Anna Truini, Ila Datar, Ryan Sowell, Anna Wurtz, Weilai Dong, Guoping Cai, Mary Ann Melnick, Victor Y Du, Joseph Schlessinger, Sarah B Goldberg, Anne Chiang, Miguel F Sanmamed, Ignacio Melero, Jackeline Agorreta, Luis M Montuenga, Richard Lifton, Soldano Ferrone, Paula Kavathas, David L Rimm, Susan M Kaech, Kurt A Schalper, Roy S Herbst, Katerina Politi
Mechanisms of acquired resistance to immune checkpoint inhibitors (ICIs) are poorly understood. We leveraged a collection of 14 ICI-resistant lung cancer samples to investigate whether alterations in genes encoding HLA Class I antigen processing and presentation machinery (APM) components or interferon signaling play a role in acquired resistance to PD-1 or PD-L1 antagonistic antibodies. Recurrent mutations or copy number changes were not detected in our cohort. In one case, we found acquired homozygous loss of B2M that caused lack of cell surface HLA class I expression in the tumor and a matched patient-derived xenograft (PDX)...
October 12, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29025424/understanding-immune-phenotypes-in-human-gastric-disease-tissues-by-multiplexed-immunohistochemistry
#16
Le Ying, Feng Yan, Qiaohong Meng, Xiangliang Yuan, Liang Yu, Bryan R G Williams, David W Chan, Liyun Shi, Yugang Tu, Peihua Ni, Xuefeng Wang, Dakang Xu, Yiqun Hu
BACKGROUND: Understanding immune phenotypes and human gastric disease in situ requires an approach that leverages multiplexed immunohistochemistry (mIHC) with multispectral imaging to facilitate precise image analyses. METHODS: We developed a novel 4-color mIHC assay based on tyramide signal amplification that allowed us to reliably interrogate immunologic checkpoints, including programmed death-ligand 1 (PD-L1), cytotoxic T cells (CD8(+)T) and regulatory T cells (Foxp3), in formalin-fixed, paraffin-embedded tissues of various human gastric diseases...
October 12, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29023959/pembrolizumab-for-metastatic-hepatocellular-carcinoma-following-live-donor-liver-transplantation-the-silver-bullet
#17
A Rammohan, M S Reddy, M Farouk, J Vargese, M Rela
Therapeutic options for extrahepatic metastases following Liver Transplantation(LT) for Hepatocellular carcinoma(HCC) are limited, and the prognosis remains poor. Innovative blockade of immune checkpoints, such as monoclonal antibodies against programmed death receptor 1 have shown promise in the treatment of solid organ malignancies. Here, we report a case of metastatic HCC after LT, where Pembrolizumab was started following a poor response with Sorafenib. There was a complete radiological response to the drug with no liver graft rejection or dysfunction...
October 10, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29023643/improved-survival-of-patients-with-melanoma-brain-metastases-in-the-era-of-targeted-braf-and-immune-checkpoint-therapies
#18
Sarah Sloot, Yian A Chen, Xiuhua Zhao, Jamie L Weber, Jacob J Benedict, James J Mulé, Keiran S Smalley, Jeffrey S Weber, Jonathan S Zager, Peter A Forsyth, Vernon K Sondak, Geoffrey T Gibney
BACKGROUND: The development of brain metastases is common for systemic treatment failure in patients with melanoma and has been associated with a poor prognosis. Recent advances with BRAF and immune checkpoint therapies have led to improved patient survival. Herein, the authors evaluated the risk of de novo brain metastases and survival among patients with melanoma brain metastases (MBM) since the introduction of more effective therapies. METHODS: Patients with unresectable AJCC stage III/IV melanoma who received first-line systemic therapy at Moffitt Cancer Center between 2000 and 2012 were identified...
October 12, 2017: Cancer
https://www.readbyqxmd.com/read/29023417/control-of-nk-cell-activation-by-immune-checkpoint-molecules
#19
REVIEW
Asma Beldi-Ferchiou, Sophie Caillat-Zucman
The development of cancer and chronic infections is facilitated by many subversion mechanisms, among which enhanced expression of immune checkpoints molecules, such as programmed death-1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), on exhausted T cells. Recently, immune checkpoint inhibitors have shown remarkable efficiency in the treatment of a number of cancers. However, expression of immune checkpoints on natural killer (NK) cells and its functional consequences on NK cell effector functions are much less explored...
October 12, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29023264/survival-trends-among-patients-with-metastatic-melanoma-in-the-pretargeted-and-the-post-targeted-era-a-us-population-based-study
#20
Dipesh Uprety, Amir Bista, Adithya Chennamadhavuni, Abesh Niroula, Syed Imran Mustafa Jafri, Angela Smith, Lubina Arjyal
In 2011, ipilimumab was approved by the US Food and Drug Administration (FDA) for metastatic melanoma. Since its approval, numerous targeted therapies have been approved by the FDA. Population-based studies assessing the survival benefit from these agents are lacking. We therefore carried out this study to compare the 1-year, 2-year, and median overall survival (OS) among metastatic melanoma patients in pretargeted and post-targeted eras. This is a retrospective study that utilized the Surveillance, Epidemiology, and End Results (SEER-18) database, version 8...
October 11, 2017: Melanoma Research
keyword
keyword
41555
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"